Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

计划入组 17 人 · 首次发布于 2020 年 11 月 23 日

Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome

计划入组 28 人 · 首次发布于 2008 年 5 月 23 日

Anti IL-18 (GSK1070806) in Behcet's Disease

计划入组 12 人 · 首次发布于 2018 年 5 月 11 日

modified IL-18

ZD55-IL-18

gene therapy (AAV, primary Sjogren's syndrome)

Simcha Il 18, Inc.

United States

ALPORT SYNDROME FOUNDATION

United States

PRIMARY PHARMACEUTICALS, INC.

United States

AB2 Bio and Nippon Shinyaku Strike $686M Deal for Rare Disease Drug Tadekinig Alfa

Nippon Shinyaku Exercises $30 Million U.S. Commercialization Option for AB2 Bio's Tadekinig Alfa in Ultra-Rare Pediatric Hyperinflammatory Syndrome

Nippon Shinyaku Exercises Option for AB2 Bio's Tadekinig Alfa, Securing U.S. Commercialization Rights for Rare Autoinflammatory Diseases